- Home
- TKNO vs XFOR Comparison
TKNO vs XFOR Comparison
Compare TKNO & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- XFOR
- Stock Information
- Founded
- TKNO 1996
- XFOR 2014
- Country
- TKNO United States
- XFOR United States
- Employees
- TKNO N/A
- XFOR N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TKNO Health Care
- XFOR Health Care
- Exchange
- TKNO Nasdaq
- XFOR Nasdaq
- Market Cap
- TKNO 340.9M
- XFOR 320.0M
- IPO Year
- TKNO 2021
- XFOR N/A
- Fundamental
- Price
- TKNO $4.87
- XFOR $3.46
- Analyst Decision
- TKNO
- XFOR Strong Buy
- Analyst Count
- TKNO 0
- XFOR 3
- Target Price
- TKNO N/A
- XFOR $34.17
- AVG Volume (30 Days)
- TKNO 186.4K
- XFOR 1.7M
- Earning Date
- TKNO 11-06-2025
- XFOR 11-05-2025
- Dividend Yield
- TKNO N/A
- XFOR N/A
- EPS Growth
- TKNO N/A
- XFOR N/A
- EPS
- TKNO N/A
- XFOR N/A
- Revenue
- TKNO $38,923,000.00
- XFOR $33,979,000.00
- Revenue This Year
- TKNO $9.52
- XFOR $1,307.51
- Revenue Next Year
- TKNO $15.20
- XFOR N/A
- P/E Ratio
- TKNO N/A
- XFOR N/A
- Revenue Growth
- TKNO 11.40
- XFOR 2925.74
- 52 Week Low
- TKNO $3.94
- XFOR $1.35
- 52 Week High
- TKNO $10.37
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- TKNO 43.67
- XFOR 48.49
- Support Level
- TKNO $4.56
- XFOR $2.96
- Resistance Level
- TKNO $5.32
- XFOR $4.15
- Average True Range (ATR)
- TKNO 0.36
- XFOR 0.30
- MACD
- TKNO -0.09
- XFOR 0.01
- Stochastic Oscillator
- TKNO 27.82
- XFOR 30.91
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.